Trial Profile
The efficacy and the utility of switching into glucagon like peptide-1 receptor agonist plus basal insulin therapy in type 2 diabetic patients treated with Basal-Bolus therapy.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 May 2019
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary) ; Liraglutide (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 23 May 2018 New trial record